Contrave vs Wegovy: Which Weight Loss Drug Fits Which Person?

Contrave and Wegovy are both FDA-approved for chronic weight management in adults, and that is about where the similarity ends. One is a twice-daily pill that targets craving. The other is a weekly injection that targets appetite through a gut hormone pathway. They produce very different amounts of weight loss, cost very different amounts, and suit different people.

Here is the comparison in full.

What is Contrave and how does it work?

Contrave is a fixed-dose extended-release combination of naltrexone and bupropion, approved by the FDA on September 10, 2014 for adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition such as high blood pressure, type 2 diabetes or dyslipidemia [1].

The two ingredients are both old drugs repurposed. Naltrexone is an opioid antagonist used for alcohol and opioid use disorder. Bupropion is a norepinephrine-dopamine reuptake inhibitor used as an antidepressant and for smoking cessation.

The rationale is that bupropion stimulates POMC neurons in the hypothalamus, which reduces appetite, but those neurons release beta-endorphin, which feeds back and shuts them down again. Naltrexone blocks that feedback loop, letting the appetite signal keep going. Naltrexone also dampens the mesolimbic dopamine circuit, the brain’s reward system [2]. The manufacturer describes it as the only FDA-approved two-in-one combination targeting both the reward system and the hypothalamus [2].

It is distributed by Currax Pharmaceuticals and is brand-only, with no generic.

What is Wegovy and how does it work?

Wegovy is semaglutide 2.4 mg, a once-weekly subcutaneous injection approved in 2021 for chronic weight management. It is a GLP-1 receptor agonist: a modified version of a hormone your gut releases after eating. It slows gastric emptying, increases insulin release when blood sugar is high, and acts on appetite centers in the brain.

An oral version of high-dose semaglutide, the Wegovy pill, was approved on December 22, 2025 and launched in early January 2026, which changes the “pill versus injection” part of this comparison for some people. In its OASIS 4 trial it produced roughly 17% mean weight loss at 64 weeks among participants who stayed on treatment, and about 14% regardless of discontinuation.

How much weight does each one produce?

This is the decisive difference.

Contrave, from the four pivotal COR trials [3]:

Trial	Contrave 32/360 mg (ITT)	Placebo (ITT)	≥5% loss	≥10% loss
COR-I (n=538 vs 536)	−5.4%	−1.3%	42% vs 17%	21% vs 7%
COR-II (n=820 vs 474)	−5.6%	−1.2%	47.9% vs 16.9%	28.1% vs 6.1%
COR-BMOD (n=565 vs 196)	−8.1%	−4.9%	57% vs 43%	35% vs 21%
COR-Diabetes (n=321 vs 166)	−3.7%	−1.7%	36% vs 18%	15% vs 5%

Two things stand out. First, COR-BMOD produced the best result, but it also paired the drug with intensive behavior modification, and the placebo group in that trial lost 4.9% on its own. Second, COR-Diabetes produced the weakest result, which is a common pattern: weight loss is harder in people with type 2 diabetes.

Pooled across the four trials, the placebo-subtracted mean weight loss at one year was 4.7%, with a range of 3.2% to 5.2% [4].

The completer figures look better because a lot of people stopped. In COR-I, 49.2% of the Contrave group and 50.1% of the placebo group discontinued study drug [5]. Among those who finished, Contrave produced 8.1% versus 1.8% on placebo, and in COR-BMOD 11.5% versus 7.3% [3]. The manufacturer’s consumer materials quote completer numbers of around 25 pounds lost at 56 weeks versus 16 pounds on placebo, with an intent-to-treat equivalent of about 18 pounds versus 11 [2][6].

Wegovy: 14.9% at 68 weeks in STEP 1 versus 2.4% on placebo, and 13.7% (15.0 kg) at 72 weeks in the SURMOUNT-5 head-to-head trial [7].

So on the same intent-to-treat basis, Wegovy produces roughly two and a half to three times more weight loss than Contrave.

A 2016 network meta-analysis of 29,018 participants put naltrexone-bupropion in the middle of the older drugs: 55% of patients reached 5% weight loss versus 23% on placebo (odds ratio 3.96), behind phentermine-topiramate at 75% and liraglutide at 63% [8].

What about the boxed warning?

This is the part people are least likely to know before they start.

Contrave carries a boxed warning for suicidal thoughts and behaviors, inherited from bupropion. The FDA’s warning alerts health care professionals and patients to the increased risk of suicidal thoughts and behaviors associated with antidepressant drugs, and notes that serious neuropsychiatric events have been reported in patients taking bupropion for smoking cessation [1][9].

Contrave is not approved for major depressive disorder or other psychiatric disorders [9].

The contraindication list is long and specific: uncontrolled hypertension, seizure disorder, bulimia or anorexia nervosa, chronic opioid or opiate agonist use or acute opiate withdrawal, abrupt discontinuation of alcohol, benzodiazepines, barbiturates or antiepileptic drugs, MAOI use, and any other bupropion-containing or naltrexone-containing product [9]. Bupropion lowers the seizure threshold, which is why a seizure history is a hard stop.

Common side effects are nausea, constipation, headache, insomnia, dizziness and raised blood pressure and heart rate. The label notes the effect of Contrave on cardiovascular morbidity and mortality has not been established [9].

Wegovy’s risk profile is different: predominantly gastrointestinal, with a boxed warning for thyroid C-cell tumors based on rodent data, plus pancreatitis and gallbladder concerns. See this site’s safety lane for the full picture.

Neither warning is a reason to rule a drug out by itself. Both are reasons to have a specific conversation with a prescriber about your history.

What does each one cost?

Contrave is the cheaper option for most people, and the gap has narrowed but not closed.

Contrave. Brand-only. With commercial insurance, a manufacturer copay card can bring it to as little as $20 per month. If you are uninsured or underinsured, the patient assistance program provides a month of medication for $99 or less [10]. Currax has also made a cash price available through GoodRx [11].

Wegovy. NovoCare Pharmacy self-pay is $349 per month for standard doses (0.25 mg through 2.4 mg) and $399 for Wegovy HD 7.2 mg. Patients new to the savings offer pay $199 per month for the 0.25 mg and 0.5 mg doses for the first two monthly fills, an offer running through December 31, 2026 [12]. With commercial insurance that covers weight-loss drugs, copays can drop to as little as $0 per fill. List price is roughly $1,349 per month.

The Wegovy pill runs about $149 to $299 per month self-pay, which narrows the price gap considerably if an oral option is what you were after.

Coverage is the dominant variable. If your plan covers Wegovy, the cost comparison changes completely. If it does not, Contrave’s $99 patient assistance price is genuinely accessible in a way that $349 is not for many households.

Who is each one actually for?

Contrave tends to fit when:

• Your main struggle is cravings, food reward and snacking rather than portion size at meals. That is what the drug was designed around [2].
• You also have depression or want help quitting smoking, since bupropion addresses both.
• You cannot take a stimulant, ruling out phentermine and Qsymia.
• You want an oral drug and cost rules out the oral incretins.
• A 5% weight reduction would meaningfully improve your health.

Wegovy tends to fit when:

• You need 10% or more weight reduction. The Obesity Association’s 2026 Standards of Care point specifically to tirzepatide or semaglutide at that threshold [13].
• You have type 2 diabetes, cardiovascular disease, sleep apnea, chronic kidney disease or another condition where semaglutide carries indication-specific evidence.
• You have a seizure history, an eating disorder history, uncontrolled hypertension or opioid use that rules out Contrave.
• Your insurance covers it.

Neither is right when: you are pregnant or planning pregnancy; both are contraindicated.

What does the professional guidance say?

The Obesity Association, a division of the American Diabetes Association, published its “Pharmacologic Treatment of Obesity in Adults” chapter on January 13, 2026. It includes a Grade A recommendation to offer obesity medications as part of initial treatment for adults with or at high risk of obesity-related diseases or complications [13].

Its framework is built around the weight reduction a patient needs. If 10% or more is the target, tirzepatide or semaglutide. If 5% to 10%, phentermine-topiramate. If less than that would achieve the clinical goal, naltrexone-bupropion, liraglutide, phentermine alone and orlistat are all reasonable considerations [13].

By condition, it lists naltrexone-bupropion as a potential-benefit option in type 2 diabetes, behind tirzepatide, semaglutide and liraglutide which have demonstrated benefit [13].

That is a fair summary of where Contrave sits in 2026: a legitimate option, not a first-line one for large weight reduction.

The practical differences nobody mentions

Dosing complexity. Contrave requires a four-week titration up to two tablets twice daily, four tablets a day total. Wegovy is one injection a week. If adherence is your weak point, that matters.

Tablets cannot be split. The extended-release coating means Contrave tablets must not be chewed, divided or crushed [9].

Blood pressure monitoring. Contrave can raise blood pressure and heart rate, and the label calls for monitoring, especially in the first months.

Alcohol. Contrave contains naltrexone, which affects opioid receptors, and bupropion, which interacts with abrupt alcohol discontinuation. This is worth a specific conversation.

The short version

Contrave is a real, FDA-approved drug with about a 5% average weight effect at one year, a craving-focused mechanism, a long contraindication list, a boxed warning, and a price as low as $20 to $99 a month.

Wegovy produces roughly 14% to 15%, comes as a weekly injection or now a daily pill, has a different risk profile, and costs $199 to $349 a month self-pay unless insurance covers it.

If you need a large weight reduction and can access a GLP-1, the evidence points there. If a GLP-1 is off the table for reasons of cost, contraindication or tolerance, Contrave is one of a small number of genuinely evidence-backed alternatives, and cravings are the specific problem it was built to address.

This article summarizes what the FDA-approved label and Instructions for Use, published trials and professional guidelines report. It is not medical advice and does not recommend a drug or a dose. Follow your own prescription and the directions your prescriber and pharmacist give you. Talk to a healthcare provider before starting, stopping or changing any medication, and tell them about every medication and supplement you take.

Sources

1. HCPLive — FDA approves Contrave for weight loss in obese adults: https://www.hcplive.com/view/fda-approves-contrave-for-weight-loss-in-obese-adults
2. Contrave for healthcare professionals — mechanism and trial results: https://contravehcp.com
3. Naltrexone/bupropion ER (Contrave) review with COR trial table: https://pmc.ncbi.nlm.nih.gov/articles/PMC4771085
4. Naltrexone/bupropion: an investigational combination for weight loss and maintenance: https://pmc.ncbi.nlm.nih.gov/articles/PMC6444555
5. FDA label, Contrave (naltrexone HCl and bupropion HCl) extended-release tablets: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf
6. Contrave — results: https://contrave.com/results
7. Eli Lilly — SURMOUNT-5 complete results published in NEJM: https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy
8. CardioSmart / American College of Cardiology — Khera 2016 network meta-analysis summary: https://www.cardiosmart.org/news/2016/7/study-confirms-the-benefits-of-fda-approved-weight-loss-pills
9. FDA label, Contrave — boxed warning and contraindications: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/200063s020lbl.pdf
10. GoodRx — Phentermine alternatives: 6 weight-loss medications to consider (Contrave savings detail): https://www.goodrx.com/conditions/weight-loss/phentermine-alternatives
11. Currax Pharmaceuticals — Contrave cash price via GoodRx: https://www.curraxpharma.com/press_release/currax-expands-access-to-fda-approved-obesity-treatment-with-brand-name-contrave-with-new-cash-price-available-via-goodrx
12. NovoCare Pharmacy: https://www.novocare.com/pharmacy.html
13. Obesity Association / ADA — Standards of Care in Overweight and Obesity: pharmacologic treatment, 2026: https://reference.medscape.com/cc2/p10/standards-care-overweight-obesity-ada-guidelines-2026a1000cjs